Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension

References

• Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Cappuccio FP, Markandu ND, Sagnella GA, et al. Effects of amlodipine on urinary sodium excretion, renin--angiotensin--aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension. J Hum Hypertens 1991;5:115-19
   PubMed Web of Science ®Google Scholar
• Olson S, Oeckler R, Li X, et al. Angiotensin II stimulates nitric oxide production in pulmonary artery endothelium via the type 2 receptor. Am J Physiol Lung Cell Mol Physiol 2004;287:559-68
   Web of Science ®Google Scholar
• Karas M, Lacourciere Y, LeBlanc AR, et al. Effect of the renin--angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients. J Hypertens 2005;23:1251-60
   PubMed Web of Science ®Google Scholar
• Imanishi T, Tsujioka H, Ikejima H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008;52:563-72
   PubMed Web of Science ®Google Scholar
• Lob H, Rosenkranz AC, Breitenbach T, et al. Antioxidant and nitric oxide-sparing actions of dihydropyridines and ACE inhibitors differ in human endothelial cells. Pharmacology 2006;76:8-18
   PubMed Web of Science ®Google Scholar
• Xu B, Xiao-Hong L, Lin G, et al. Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide- and kinin-dependent mechanism. Br J Pharmacol 2002;136:375-82
   PubMed Web of Science ®Google Scholar
• Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 2007;67:1767-92
   PubMed Web of Science ®Google Scholar
• Rashid H. Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren. Curr Med Res Opin 2008;24:2627-37
   PubMed Web of Science ®Google Scholar
• Drummond W, Munger MA, Essop MR, et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens 2007;9:742-50
   PubMedGoogle Scholar
• Pedrinelli R, Dell'Omo G, Melillo E, et al. Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension 2000;35:621-5
   PubMed Web of Science ®Google Scholar
• Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich) 2003;5:330-5
   PubMedGoogle Scholar
• International Conference on Harmonization. E1: The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. In: International Conference on Harmonization, 1994
   Google Scholar
• Smith TR, Glazer R, Koren MJ, et al. Long-term safety and efficacy of combination therapy with amlodipine and valsartan in hypertensive patients. J Clin Hypertens 2008;10:A35 (Abstract P-70)
   Google Scholar
• Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009;119:417-25
   PubMed Web of Science ®Google Scholar
• Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004;17:495-501
   PubMed Web of Science ®Google Scholar
• Littlejohn T, Majul C, Oigman W, et al. Effect of telmisartan addition to amlodipine on reduction of incidence of peripheral oedema: safety analysis from a factorial study in hypertension. J Clin Hypertens 2008;10:A27 (Abstract P-51)
   Google Scholar
• Weycker D, Edelsberg J, Vincze G, et al. Blood pressure control in patients initiating antihypertensive therapy. Ann Pharmacother 2008;42:169-76
   PubMed Web of Science ®Google Scholar